Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Obese Youth With Prediabetes/Early T2D and MASLD
NCT05067621Phase 2Active, not recruiting
- Sponsor
- Yale University
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in type 2 diabetes mellitus (T2DM), impaired glucose tolerance (IGT), non-alcoholic fatty liver disease (NAFLD), sponsored by Yale University. Started Jul 2023; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)impaired glucose tolerance (IGT)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05067621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05067621.